沙库巴曲缬沙坦治疗HFmrEF伴冠心病的疗效及对患者心功能的影响  

Efficacy of Sacubitril/Valsartan in Treating HFmrEF with Coronary Heart Disease and Its Impact on Cardiac Function

作　　者：许文静 张伟燕 XU Wenjing;ZHANG Weiyan(Department of Pharmacy,Luohe Second People's Hospital,Luohe 462000,China;Department of Cardiovascular Medicine,Luohe Second People's Hospital,Luohe 462000,China)

机构地区：[1]漯河市第二人民医院药剂科,河南漯河462000 [2]漯河市第二人民医院心血管内科,河南漯河462000

出　　处：《延边大学医学学报》2025年第3期110-113,共4页Journal of Medical Science Yanbian University

基　　金：河南省医学科技攻关计划联合共建项目(编号:LHGJ20191411)。

摘　　要：目的:探讨沙库巴曲缬沙坦治疗射血分数中间值心力衰竭(HFmrEF)伴冠心病的疗效及对患者心功能的影响。方法:根据随机数字表法,将2021年6月至2023年6月漯河市第二人民医院收治的78例HFmrEF伴冠心病患者分为对照组(39例,常规治疗)与研究组(39例,将常规治疗中的缬沙坦替换为沙库巴曲缬沙坦),两组均连续治疗6个月。对比两组的疗效、不良反应发生情况、治疗前后的心功能指标及心脏重构指标。结果:研究组治疗的总有效率比对照组高(P<0.05);两组不良反应发生率对比,差异无统计学意义(P>0.05);治疗6个月后,研究组的N末端B型钠尿肽前体(NT-proBNP)水平比对照组低(P<0.05),左心室射血分数(LVEF)、每搏输出量(SV)、心输出量(CO)比对照组高(P<0.05);治疗6个月后,研究组的左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、左房内径(LAD)比对照组小(P<0.05)。结论:沙库巴曲缬沙坦治疗HFmrEF伴冠心病的疗效显著,可改善患者的心功能指标、心脏重构指标,且不会增加不良反应。Objective:To evaluate the efficacy of sacubitril/valsartan in treating heart failure with mid-range ejection fraction(HFmrEF)complicated by coronary heart disease(CHD)and its impact on cardiac function.Methods:A total of 78 HFmrEF patients with CHD admitted to Luohe Second People’s Hospital from June 2021 to June 2023 were divided into a control group(39 cases,conventional therapy)and an observation group(39 cases,replacing valsartan in conventional therapy with sacubitril/valsartan)using the random number table method.Both groups received continuous treatment for 6 months.The efficacy,incidence of adverse reactions,cardiac function parameters,and cardiac remodeling indicators were compared between the two groups before and after treatment.Results:The total effective rate in the observation group was significantly higher than that in the control group(P<0.05).No statistically significant difference was observed in the incidence of adverse reactions between the two groups(P>0.05).After 6 months of treatment,the observation group exhibited significantly lower NT-proBNP levels and smaller left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),and left atrial diameter(LAD)compared to the control group(P<0.05).Additionally,the observation group showed higher left ventricular ejection fraction(LVEF),stroke volume(SV),and cardiac output(CO)than the control group(P<0.05).Conclusion:Sacubitril/valsartan demonstrates significant efficacy in treating HFmrEF with CHD,improves cardiac function and remodeling indicators,and does not increase adverse reactions.

关 键 词：射血分数中间值心力衰竭 冠心病 沙库巴曲缬沙坦 心功能 

分 类 号：R541.4[医药卫生—心血管疾病]